NODAGA-LM3 TFA
Description
NODAGA-LM3 TFA is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC50 = 1.3 nM). NODAGA-LM3 TFA does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 TFA shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. 68Ga-labeled NODAGA-LM3 TFA can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors.
Product Information
| Product Name | NODAGA-LM3 TFA |
| Molecular Weight | 1521.11 (free acid) |
| Formula | C70H91ClF3N15O21S2.xC2HF3O2 |
| Appearance | Solid |
| Color | White to off-white |
| Sequence | {NODAGA}-{p-Cl-Phe}-{d-Cys}-Tyr-{d-Phe(4-amino-carbamoyl)}-Lys-Thr-Cys-{d-Tyr}-NH2 (Disulfide bridge: Cys2-Cys7) |
| Sequence Shortening | {NODAGA}-{p-Cl-Phe}-{d-Cys}-Y-{d-Phe(4-amino-carbamoyl)}-KTC-{d-Tyr}-NH2 (Disulfide bridge: Cys2-Cys7) |
| Storage | Sealed storage, away from moisture and light Powder -80??C 2 years -20??C 1 year *In solvent : -80??C, 6 months; -20??C, 1 month (sealed storage, away from moisture and light) ???? & ??Ʒ???? Data Sheet (561 KB) ??Ʒʹ??ָ?? (1538 KB) ?ο????? . Liu M, et al. Staging, heterogeneity analysis and early treatment response evaluation based on 68Ga-NODAGA-LM3 and 18F-FDG PET/CT in small cell lung cancer patients. 2025. ? . Zhu W, et al. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49(5): 1613-1622. ? |
